The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zlobin D.E.

Patrice Lumumba Peoples’ Friendship University of Russia

Gureeva M.A.

Patrice Lumumba Peoples’ Friendship University of Russia;
Moscow Regional Research and Clinical Institute

Molochkov A.V.

Patrice Lumumba Peoples’ Friendship University of Russia;
Moscow Regional Research and Clinical Institute

Misnikova I.V.

Moscow Regional Research and Clinical Institute

Yakubovskaya E.S.

Moscow Regional Research and Clinical Institute

Polesko I.V.

The Russian National Research Medical University named after N.I. Pirogov

Molochkov V.A.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

Guseva T.S.

Gamaleya Federal Research Centre of Epidemiology and Microbiology

Effectiveness of recombinant interferon alpha in prevention of candida infection in patients at risk

Authors:

Zlobin D.E., Gureeva M.A., Molochkov A.V., Misnikova I.V., Yakubovskaya E.S., Polesko I.V., Molochkov V.A., Guseva T.S.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2024;23(4): 405‑414

DOI: 10.17116/klinderma202423041405

Views: 632

Downloaded: 35

Download PDF (RU)
Contact the author
Table of contents

EFFECTIVENESS OF RECOMBINANT INTERFERON ALPHA IN PREVENTION OF CANDIDA INFECTION IN PATIENTS AT RISK
EFFECTIVENESS OF RECOMBINANT INTERFERON ALPHA IN PREVENTION OF CANDIDA INFECTION IN PATIENTS AT RISK

To cite this article:

Zlobin DE, Gureeva MA, Molochkov AV, et al. . Effectiveness of recombinant interferon alpha in prevention of candida infection in patients at risk. Russian Journal of Clinical Dermatology and Venereology. 2024;23(4):405‑414. (In Russ.)
https://doi.org/10.17116/klinderma202423041405

Подписка 2025-2 (Russian Journal of Clinical Dermatology and Venereology)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Impact of SGLT2 inhi­bitors on erythropoiesis and iron exchange in patients with diabetes mellitus and chro­nic heart failure. Russian Journal of Preventive Medi­cine. 2024;(5):103-110
Inci­dence of carbohydrate meta­bolism diso­rder in iron overload of different etiology. Russian Journal of Preventive Medi­cine. 2024;(5):111-117
Fatal case of rhinocerebral muco­rmycosis on the background of type II diabetes mellitus. Russian Journal of Archive of Pathology. 2024;(3):52-58
Enda­rterectomy from supe­rficial femo­ral artery in patients with type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):285-293
Evaluation of reva­scularization effi­ciency using near-infrared oximetry in patients with diabetic foot syndrome. Piro­gov Russian Journal of Surgery. 2024;(6):20-27
Features of the oral microbiota in patients with type II diabetes in the background of dental implantation. Russian Journal of Stomatology. 2024;(2):21-26
The problem of diabetes mellitus in obstetrics. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):25-29
Skin alte­rations as possible clinical markers of diabetes mellitus and meta­bolic syndrome. Russian Journal of Preventive Medi­cine. 2024;(7):101-107
Prevalence of diabetic reti­nopathy asse­ssed using two-field mydriatic fundus photography. Russian Annals of Ophthalmology. 2024;(4):60-67

The article is devoted to the study of effectiveness of interferon alpha-2b with antioxidant (alpha tocopherol acetate and ascorbic acid) in the form of rectal suppositories in the prevention of mucous membrane infection development by fungi of Candida genus in patients at risk. Patients with a proven diagnosis of diabetes mellitus at unreached target levels of glycemia were considered as a risk group. The possibility of including interferon alpha-2b drugs in the course of preventive and rehabilitation procedures in patients with past candida infection or high risk of Candida spp. infection development is being discussed.

BACKGROUND

An increase in the number of cases of Candida spp. resistance to anti-mycotic drugs is of significant concern to the medical community. Type I interferons probably play an important role in protecting the host from Candida albicans, which highlights their potential importance in developing therapeutic strategies against fungal infections.

OBJECTIVE

To assess the effect of using recombinant interferon alpha-2b with antioxidant (alpha tocopherol acetate and ascorbic acid) in the form of rectal suppositories on Candida spp. colonization in patients with risk factors of manifest candidiasis development.

MATERIAL AND METHODS

A cross-sectional single-center study was performed in groups of patients diagnosed with diabetes mellitus at unreached target levels of glycemia (HbA1c more than 7%, but less than 9%). The main methods of research were following: clinical physical examination with assessment of the mucous membranes of oral cavity and genital organs, as well as quantitative analysis of Candida spp. Colonies in swabs obtained from the mucous membranes of oral cavity and genital cavities.

RESULTS

The study shows that the use of rectal suppositories based on recombinant interferon alpha-2b has an effect on Candida spp. Colonization in patients with risk factors of manifest candidiasis development.

CONCLUSION

The study results are consistent with the data of several authors on the effectiveness of interferon alpha regarding fungi of Candida genus and the possibility of using interferon drugs as prophylactic agents to prevent the development of manifest infection process.

Keywords:

Candida spp
mucosal candidiasis
diabetes mellitus
interferon alpha

Authors:

Zlobin D.E.

Patrice Lumumba Peoples’ Friendship University of Russia

Gureeva M.A.

Patrice Lumumba Peoples’ Friendship University of Russia;
Moscow Regional Research and Clinical Institute

Molochkov A.V.

Patrice Lumumba Peoples’ Friendship University of Russia;
Moscow Regional Research and Clinical Institute

Misnikova I.V.

Moscow Regional Research and Clinical Institute

Yakubovskaya E.S.

Moscow Regional Research and Clinical Institute

Polesko I.V.

The Russian National Research Medical University named after N.I. Pirogov

Molochkov V.A.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

Guseva T.S.

Gamaleya Federal Research Centre of Epidemiology and Microbiology

Received:

21.05.2024

Accepted:

07.06.2024

List of references:

  1. Canela HMS, Cardoso B, Vitali LH, et al. Prevalence, virulence factors and antifungal susceptibility of Candida spp. isolated from bloodstream infections in a tertiary care hospital in Brazil. Mycoses. 2018;61(1):11-21. Epub 2017 Sept 22. PMID: 28940753. https://doi.org/10.1111/myc.12695
  2. Lega IC, Bronskill SE, Campitelli MA, et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019;21(11):2394-2404. https://doi.org/10.1111/dom.13820
  3. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med. 2013;125(3):33-46. PMID: 23748505. https://doi.org/10.3810/pgm.2013.05.2650
  4. Köhler JR, Hube B, Puccia R, et al. Fungi that infect humans. Microbiol Spectrum. 2017;5(3):FUNK-0014-2016. https://doi.org/10.1128/microbiolspec.FUNK-0014-2016
  5. Raja A, Park J. Disseminated Candida lusitaniae: Nosocomial Acquisition Secondary to an Indwelling Urinary Catheter. Case Rep Infect Dis. 2021; 2021:6632730. PMID: 34221522; PMCID: PMC8225443. https://doi.org/10.1155/2021/6632730
  6. Du H, Bing J, Hu T, et al. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020 Oct 22;16(10):e1008921. PMID: 33091071; PMCID: PMC7581363. https://doi.org/10.1371/journal.ppat.1008921
  7. Neville BA, d’Enfert C, Bougnoux ME. Candida albicans commensalism in the gastrointestinal tract. FEMS Yeast Res. 2015;15(7):fov081. Epub 2015 Sept 06. PMID: 26347504. https://doi.org/10.1093/femsyr/fov081
  8. Seider K, Heyken A, Lüttich A, et al. Interaction of pathogenic yeasts with phagocytes: survival, persistence and escape. Curr Opin Microbiol. 2010;13: 392-400.  https://doi.org/10.1016/j.mib.2010.05.001
  9. Moyes DL, Wilson D, Richardson JP, et al. Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature. 2016;532:64-68.  https://doi.org/10.1038/nature17625
  10. Hellstein JW, Marek CL. Candidiasis: Red and White Manifestations in the Oral Cavity. Head and Neck Pathol. 2019;13:25-32.  https://doi.org/10.1007/s12105-019-01004-6
  11. Arya NR, Rafiq NB. Candidiasis. StatPearls, StatPearls Publishing, 29 May 2023.
  12. Sinchikhin SP, Mamiev OB, Suverneva AA. Vulvovaginal Candidiasis — A Modern View on Etiology, Clinical Presentation, and Diagnostics. Astrakhan Medical Journal. 2009;3. (In Russ.). Accessed Jan 31, 2023. https://cyberleninka.ru/article/n/vulvovaginalnyy-kandidoz-sovremennyy-vzglyad-na-etiologiyu-kliniku-i-diagnostiku
  13. Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173-1178. Epub 2012 June 14. PMID: 22632452. https://doi.org/10.1185/03007995.2012.697053
  14. Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961-1971. PMID: 17560449. https://doi.org/10.1016/S0140-6736(07)60917-9
  15. Kannan R, Chellam J, Ponnusamy K. A prospective study on the isolation, culture, sub-culture and species identification of Candida from the mucosal lesions of immuno-compromised individuals. J Evolution Med Dent Sci. 2018;7(14):1741-1748. https://doi.org/10.14260/jemds/2018/393
  16. Morace G, Perdoni F & Borghi E. Antifungal drug resistance in Candida species. Journal of global antimicrobial resistance. 2014;2(4):254-259.  https://doi.org/10.1016/j.jgar.2014.09.002
  17. Sanglard D, Odds F. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. The Lancet. Infectious Diseases. 2002;2(2):73-85.  https://doi.org/10.1016/S1473-3099(02)00181-0
  18. Cowen L, Sanglard D, Howard S, et al. Mechanisms of Antifungal Drug Resistance. Cold Spring Harbor Perspectives in Medicine. 2015;57:a019752. https://doi.org/10.1101/cshperspect.a019752
  19. Perlin DS. Mechanisms of echinocandin antifungal drug resistance. Annals of the New York Academy of Sciences. 2015;1354(1):1-11.  https://doi.org/10.1111/nyas.12831
  20. Chaabane F, Graf A, Jequier L & Coste A. Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris. Frontiers in Microbiology. 2019;10:2788. https://doi.org/10.3389/fmicb.2019.02788
  21. Bartolo C, Hall V, Friedman ND, et al. Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports. BMC Infect Dis. 2021;21:284.  https://doi.org/10.1186/s12879-021-05982-3
  22. Caro MKC, Kho SA, Cunanan EC. Incidence and factors associated with genitourinary infections among Type 2 diabetes patients on SGLT2 Inhibitors: A single retrospective cohort study. Diabetes Epidemiology and Management. 2022;7:100082. ISSN 2666-9706. https://doi.org/10.1016/j.deman.2022.100082
  23. Lin YH, Lin CH, Huang YY, et al. Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: A retrospective cohort study. Diabetes Res Clin Pract. 2022;186: 109816. Epub 2022 Mar 02. PMID: 35247527. https://doi.org/10.1016/j.diabres.2022.109816
  24. Lega IC, Bronskill SE, Campitelli MA, et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019;21(11):2394-2400. Epub 2019 July 21. PMID: 31264755. https://doi.org/10.1111/dom.13820
  25. Rodríguez-Archilla A, Piedra-Rosales C. Candida species oral detection and infection in patients with diabetes mellitus: a meta-analysis. Iberoamerican Journal of Medicine. 2021;3(2):115-121.  https://doi.org/10.5281/zenodo.4495286
  26. Glucose Homeostasis Is Important for Immune Cell Viability during Candida Challenge and Host Survival of Systemic Fungal Infection. Cell Metabolism. 2018;27(5):988-1006.e7.  https://doi.org/10.1016/j.cmet.2018.03.019
  27. Harpf V, Kenno S, Rambach G, et al. Influence of Glucose on Candida albicans and the Relevance of the Complement FH-Binding Molecule Hgt1 in a Murine Model of Candidiasis. Antibiotics. 2022;11:257.  https://doi.org/10.3390/antibiotics11020257
  28. Nikolic DM, Dimitrijevic-Sreckovic V, Ranin LT, Stojanovic MM, Ilic ID, Gostiljac DM, Soldatovic IA. Homeostatic microbiome disruption as a cause of insulin secretion disorders. Candida albicans, a new factor in pathogenesis of diabetes: A STROBE compliant cross-sectional study. Medicine. 2022;101(45):e31291. https://doi.org/10.1097/MD.0000000000031291
  29. Velizarova M, Yanachkova V, Boneva T, et al. Relationship between Vitamin D status and microbiome changes in Bulgarian patients with type 2 diabetes mellitus, Biotechnology & Biotechnological Equipment. 2023;37:1.  https://doi.org/10.1080/13102818.2023.2209662
  30. Abuqwider J, Corrado A, Scidà G, et al. Gut microbiome and blood glucose control in type 1 diabetes: a systematic review. Front Endocrinol (Lausanne). 2023;14:1265696. PMID: 38034007; PMCID: PMC10684760. https://doi.org/10.3389/fendo.2023.1265696
  31. Ferlita S, Yegiazaryan A, Noori N, et al. Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis. J Clin Med. 2019;8:2219. https://doi.org/10.3390/jcm8122219
  32. Halimi A, Mortazavi N, Memarian A, et al. The relation between serum levels of interleukin 10 and interferon-gamma with oral candidiasis in type 2 diabetes mellitus patients. BMC Endocr Disord. 2022;22:296.  https://doi.org/10.1186/s12902-022-01217-x
  33. Ruhnke M. Skin and Mucous Membrane Infections. ASM Press: Candida and Candidiasis. 2002:307-325. 
  34. d’Enfert C, Kaune AK, Alaban LR, et al. The impact of the Fungus- Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives. FEMS Microbiol Rev. 2021;45(3):fuaa060. PMID: 33232448; PMCID: PMC8100220. https://doi.org/10.1093/femsre/fuaa060
  35. Smeekens SP, Ng A, Kumar V, Johnson MD, et al. Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun. 2013;4:1342. PMID: 23299892; PMCID: PMC3625375. https://doi.org/10.1038/ncomms2343
  36. Li T, Niu X, Zhang X, et al. Recombinant Human IFNα-2b Response Promotes Vaginal Epithelial Cells Defense against Candida albicans. Front Microbiol. 2017;8:697. PMID: 28473823; PMCID: PMC5397410. https://doi.org/10.3389/fmicb.2017.00697
  37. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res. 1999; 19(8):817-828. PMID: 10476925. https://doi.org/10.1089/107999099313325
  38. Li T, Liu Z, Zhang X, et al. Therapeutic effectiveness of type I interferon in vulvovaginal candidiasis. Microb Pathog. 2019;134:103562. Epub 2019 May 31. PMID: 31158491. https://doi.org/10.1016/j.micpath.2019.103562
  39. Haruna Y, Inoue A. Minimal Dose Interferon Suppository Treatment Suppresses Viral Replication with Platelet Counts and Serum Albumin Levels Increased in Chronically Hepatitis C Virus-Infected Patients: A Phase 1b, Placebo-Controlled, Randomized Study. Journal of Interferon & Cytokine Research. 2014;10:111-116.  https://doi.org/10.1089/jir.2013.0021
  40. Zhou Y, Cheng L, Lei YL, et al. The interactions between Candida albicans and mucosal immunity. Front Microbiol. 2021;12:652725. https://doi.org/10.3389/fmicb.2021.652725
  41. Samaranayake LP, Keung Leung W, Jin L. Oral mucosal fungal infections. Periodontol 2000. 2009;49:39-59. PMID: 19152525. https://doi.org/10.1111/j.1600-0757.2008.00291.x
  42. Lamey P-J, Darwaza A, Fisher BM, et al. Secretor status, candidal carriage and candidal infection in patients with diabetes mellitus. J Oral Pathol Med. 1988;17:354-357.  https://doi.org/10.1111/j.1600-0714.1988.tb01549.x
  43. Budtz-Jörgensen E. Clinical aspects of Candida infection in denture wearers. J Am Dent Assoc. 1978;96(3):474-479. PMID: 272429. https://doi.org/10.14219/jada.archive.1978.0088
  44. Lionakis MS, Netea MG. Candida and Host Determinants of Susceptibility to Invasive Candidiasis. PLOS Pathogens. 2013;9(1):e1003079. https://doi.org/10.1371/journal.ppat.1003079
  45. Playford EG, Eggimann P, Calandra T. Antifungals in the ICU. Current Opinion in Infectious Diseases. 2008;21(6):610-619.  https://doi.org/10.1097/qco.0b013e3283177967
  46. Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med. 1995;123(3):205-215. PMID: 7598303. https://doi.org/10.7326/0003-4819-123-3-199508010-00008
  47. Katzenmeyer KN, Szott LM, Bryers JD. Artificial opsonin enhances bacterial phagocytosis, oxidative burst and chemokine production by human neutrophils. Pathog Dis. 2017;75(6):ftx075. PMID: 28859309; PMCID: PMC5827578. https://doi.org/10.1093/femspd/ftx075
  48. Suprewicz Ł, Skłodowski K, Walewska A, Deptuła P, Sadzyńska A, Eljaszewicz A, Moniuszko M, Janmey PA, Bucki R. Plasma Gelsolin Enhances Phagocytosis of Candida auris by Human Neutrophils through Scavenger Receptor Class B. Microbiol Spectr. 2023;11:e04082-22.  https://doi.org/10.1128/spectrum.04082-22

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.